Condition
Hidradenitis Suppurativa (Acne Inversa)
Total Trials
6
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (1)
P 4 (2)
Trial Status
Not Yet Recruiting3
Completed1
Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06237465Phase 4Withdrawn
Botulinum Toxin-A for Hidradenitis Suppurativa
NCT07261072Phase 4Not Yet Recruiting
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
NCT06926192Recruiting
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
NCT06731309Not ApplicableNot Yet RecruitingPrimary
HS ABSCESSES: I&D VS PUNCH DEBRIDEMENT
NCT05762484Not ApplicableNot Yet RecruitingPrimary
Efficacy of Laser Hair Removal Therapy in HS
NCT02421172Phase 2CompletedPrimary
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
Showing all 6 trials